Updated on 29 June 2016
To begin with, could you give our BioSpectrum readers a short description about Catalent?
Combining world-class talent with cutting-edge technology, Catalent was created in April 2007 when The Blackstone Group, a premier global investment and advisory firm, acquired the Pharmaceutical Technologies and Services segment of Cardinal Health. The acquisition created a global network of experts and facilities dedicated to the advanced development, delivery, and supply of drugs and consumer health products.
Today, Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years' serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs more than8,500 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Its headquarters are in Somerset, NJ, in the United States.
What is Catalent's USP and how have your products/technologies disrupted the life sciences market?
As experts in improving drug performance, Catalent is globally renowned for bringing numerous innovations to market. Following the invention of the continuous softgel manufacturing process by RP Scherer in the 1930s, Catalent's softgel capsules have gained widespread acceptance and are now the preferred dose form for many prescribed drugs, OTC medications and health supplements. Catalent has continued the development of this flexible delivery technology for over eight decades, including the 2001 launch of Vegicaps, a vegetable-based softgel shell system.
In the 1980s, Catalent introduced its Zydis technology, a unique Orally Disintegrating Tablet (ODT) technology, which is a freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water.
Further innovations have included the introduction of Catalent's proprietary GPEx technology, which creates stable, high-yielding mammalian cell lines with high speed and efficiency, getting customer's drug development projects to clinic in one-third the time of traditional approaches. The advantages of applying GPEx technology span from early feasibility studies, to clinical manufacturing, to commercial scale production.